Markers of Vitamin B12 Status in Relation to Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Cognitive Performance
Annals of Neurology · 2023
DOI: 10.1002/ana.26673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, 2023. Verfasst von Babak Hooshmand und 7 weiteren Autor:innen. Beteiligte Einrichtung: Aging Research Center, Karolinska Institute, Stockholm, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, Vitamin B 12 Deficiency, Cognitive Dysfunction. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
The association between markers of vitamin B12 status and cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD), which precede cognitive impairment, has been investigated by only a few small studies and results have been inconsistent.
Aim
The aim of this study was to investigate the associations of vitamin B12‐related markers with CSF biomarkers of AD and cognitive performance.
Methods
Data included 462 patients aged 40 to 94 years referred to the Memory Clinic of the Ulm University Hospital, Ulm, Germany. Vitamin B12, holotranscobalamin (HoloTC), homocysteine (tHcy), and methylmalonic acid (MMA) have been measured. CSF values of amyloid β 42 (Aβ 42 ) and total‐tau have been assessed in 227 participants. CERAD battery was administered to examine the cognitive status, and different domains were derived. Regression models were used to investigate the associations.
Results
In the multi‐adjusted model, higher levels of MMA were associated with raised CSF total‐tau values: the odds ratios (ORs) 95% confidence intervals (CIs) were 3.25 (95% CI = 1.35–7.76) for the highest quartile of MMA compared to the lowest. Furthermore, moderately increased MMA were related to lower Aβ 42 levels: the ORs and 95% CIs were 3.06 (95% CI = 1.22–7.67) for the third quartile of MMA compared to the lowest. All B12 indicators except B12 itself were related to several cognitive domains, such as episodic memory and executive functioning.
Conclusions
Markers of vitamin B12 may be independent predictors of CSF biomarkers of AD and cognitive functioning, with MMA showing the most consistent effects. Randomized controlled trials are needed to determine the importance of vitamin B12 supplementation on slowing structural brain changes and cognitive decline. ANN NEUROL 2023;94:223–231
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Aging Research Center, Karolinska Institute, Stockholm, Sweden.
- Department of Geriatric Medicine (B.H.), Klinikum Ingolstadt, Germany.
- Department of Psychiatry and Psychotherapy, University Hospital LMU Munich, Munich, Germany.
- Department of Neurology, Ulm University Hospital, Ulm, Germany.
- Psychiatric Services Thurgau, Münsterlingen, Switzerland.
- German Center for Neurodegenerative Disorders (DZNE), Munich, Germany.
ORCID-Profile: Babak Hooshmand
Zitieren
APA
Hooshmand, B., Appold, F., Fissler, P., Perneczky, R., Otto, M., Tumani, H., Kivipelto, M., & von Arnim, C. A. F. (2023). Markers of Vitamin B12 Status in Relation to Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Cognitive Performance. Annals of Neurology. https://doi.org/10.1002/ana.26673
Vancouver
Hooshmand B, Appold F, Fissler P, Perneczky R, Otto M, Tumani H, et al. Markers of Vitamin B12 Status in Relation to Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Cognitive Performance. Annals of Neurology. 2023. doi:10.1002/ana.26673
BibTeX
@article{Hooshmand2023,
author = {Hooshmand, Babak and Appold, Franziska and Fissler, Patrick and Perneczky, Robert and Otto, Markus and Tumani, Hayrettin and Kivipelto, Miia and von Arnim, Christine A F},
title = {Markers of Vitamin B12 Status in Relation to Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Cognitive Performance},
journal = {Annals of Neurology},
year = {2023},
doi = {10.1002/ana.26673}
}
EUVIMED